Evidence map›Paper›PMID 42088563›Full record

ArticleMaterials today. Bio2026

An entropy-driven, selective copper-sequestering coordination framework for gut-restricted intervention of Wilson's disease.

Tianzhi Liu, Yao Xiao, Xiaolin Cui, Futao Tang, Yuan Cheng, Xin Zhao, Liang Xiang, Yuge Wu, Shiyi Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tianzhi LiuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Yao XiaoSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Xiaolin CuiSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Futao TangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Yuan ChengSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Xin ZhaoSuzhou Intelligem Pharmaceutical Technology Co., LTD, Suzhou, People's Republic of China.
Liang XiangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Yuge WuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Shiyi ZhangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant Copper (Cu) accumulation drives diverse tissue pathologies as amplified in Wilson's Disease. However, current FDA-approved Cu-lowering agents (triethylenetetramine and zinc acetate) still suffer from poor ion selectivity, Cu-redistribution effect, and slow-onset with extended dosing. Herein, we propose a gut-restricted copper sequestration strategy to relieve the Cu burden based on Prussian blue analogues (PBAs). Through the synthesis and screening of 28 Zn-based PBAs crystals, we identify a trigonal, and water-deficient Zn

Indexed as

Copper-driven pathologiesCopper sequestrationGut-restricted agentsPrussian blue analoguesWilson's disease

Identifiers

PMID42088563
PMCPMC13138040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.